Evidence map›Paper›PMID 18560751›Full record

ArticleInternational journal of hematology2008

Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan.

Yasuhito Nannya, Hiromitsu Yokota, Yumiko Sato, Go Yamamoto, Takashi Asai, Motoshi Ichikawa, Takuro Watanabe, Keiki Kumano, Akira Hangaishi, Tsuyoshi Takahashi and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yasuhito NannyaDepartment of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Hiromitsu YokotaDepartment of Clinical Laboratory Medicine, Graduate School of Medicine, Tokyo University, Tokyo, Japan.
Yumiko SatoDepartment of Clinical Laboratory Medicine, Graduate School of Medicine, Tokyo University, Tokyo, Japan.
Go YamamotoDepartment of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Takashi AsaiDepartment of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Motoshi IchikawaDepartment of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Takuro WatanabeDepartment of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Keiki KumanoDepartment of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Akira HangaishiDepartment of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Tsuyoshi TakahashiDepartment of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Shigeru ChibaDepartment of Cell Therapy and Transplantation, Graduate School of Medicine, Tokyo University, Tokyo, Japan.
Yutaka YatomiDepartment of Clinical Laboratory Medicine, Graduate School of Medicine, Tokyo University, Tokyo, Japan.
Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. kurokawa-tky@umin.ac.jp.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

We retrospectively analyzed the clinical outcome of chronic myelogenous leukemia (CML) patients who received imatinib mesylate (IM) as initial therapy at Tokyo University Hospital. In all patients, molecular response as well as hematological and cytogenetic response was measured routinely. Our cohort showed respectable outcome with complete cytogenetic response (CR) of 82% in 1 year, and 97% in 5 years. The estimated progression free survival of 29 patients who were in chronic phase at diagnosis was 97% and the estimated OS was 92.4% at 5 years. Although IM interruption due to side effects was observed in about half of the cases, the discontinuation was only temporary in all cases. However, patients who showed persistent intolerance with adequate dose of IM (300 mg/day or more) showed poor molecular response.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesDisease-Free SurvivalDose-Response Relationship, DrugDrug Resistance, NeoplasmFemaleFusion Proteins, bcr-ablHumansImatinib MesylateJapanLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleAntineoplastic AgentsBenzamidesFusion Proteins, bcr-ablImatinib MesylatePiperazinesPyrimidines

Identifiers

PMID18560751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.